Enviomycin
![]() | |
Systematic (IUPAC) name | |
---|---|
3,6-diamino-N-[(3R,6Z)-3-(2-amino-3,4,5,6-tetrahydropyrimidin-4-yl)-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]-4-hydroxyhexanamide | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Routes of administration | IM |
Legal status |
|
Identifiers | |
CAS Number |
33103-22-9 ![]() |
ATC code | none |
PubChem | CID 3032903 |
DrugBank |
DB08993 ![]() |
ChemSpider |
16736480 ![]() |
UNII |
XU299C23A2 ![]() |
KEGG |
D07897 ![]() |
ChEMBL | CHEMBL2146142 |
Chemical data | |
Formula | C25H43N13O10 |
Molar mass | 685.69 g/mol |
| |
| |
![]() ![]() |
Enviomycin (INN, also called tuberactinomycin N) is an antibiotic drug, isolated from Streptomyces griseoverticillatus var. tuberacticus.[1] It is used in the treatment of tuberculosis.[2]
References
- ↑ Jinnosuke Abe et al. Antibiotic Tuberactinomycin-N and process for production thereof. US patent 3892732
- ↑ Selvakumar, N; Kumar, V; Acharyulu, GS; Rehman, F; Paramasivan, CN; Prabhakar, R (1992). "Susceptibility of south Indian strains of Mycobacterium tuberculosis to tuberactinomycin". The Indian journal of medical research 95: 101–4. PMID 1506058.
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.